Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
Launching Acoustic Force Spectroscopy - unlocking the potential of biomolecular bungee jumping (ACOFORS)

Framework: Horizon 2020 — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Proof of concept grants
Action type: ERC actions
Countries involved: Netherlands
Call: ERC Proof of Concept Grant (ERC-2014-PoC, 2014)
Start date: 2015-07-01
End date: 2016-06-30
Duration (months): 12.0
Total project cost (EUR): 150000.0
EU funding (EUR): 150000.0
Participants: 1
Project status: CLOSED

ACOFORS has been designed with the ultimate goal of preparing commercialisation of Acoustic Force Spectroscopy (AFS). AFS is a completely new and powerful technique for determining biomolecular mechanics and structure of single molecules such as DNA and proteins. These studies are performed on a large scale by biologists and within pharmaceutical companies for e.g. drug discovery and development. Current technologies for force spectroscopy (FS) represent a $50+ million market, but are expensive, require high levels of specialism and are laborious. AFS, invented in the laboratory of Prof. Wuite, is much simpler to use, can be operated in high-throughput mode and can become available at relative low cost. As such, AFS vastly expands the possibilities of FS and makes it available to a much wider community. This makes AFS a very attractive technology for science and business, both from the perspective of the user and of the seller. In ACOFORS, a team of scientists and business developers will transform the current prototype in a marketable product, strengthen the intellectual property position, build a solid business case based on an extensive market analysis and take steps towards licensing the technology to industry.

Keywords: force spectroscopy,single molecule force spectroscopy,protein analysis,ultrasound,molecular biology,high throughput,commercialisation
4x4, demonstrating a flexible value chain to utilize biomass functionalities in the processing industry (Bio4Products)

Framework: Horizon 2020 — Industrial Leadership
Programme: Nanotechnologies, Advanced Materials, Advanced Manufacturing and Processing, and Biotechnology
Theme: Sustainable, resource-efficient and low-carbon technologies in energy-intensive process industries
Action type: Innovation actions
Countries involved: Germany,Belgium,Belgium,Belgium,Finland,Netherlands,Netherlands,Netherlands,United Kingdom
Call: Industrial technologies for the valorisation of European bio-resources into high added value process streams (H2020-SPIRE-2016, 2016)
Start date: 2016-09-01
End date: 2021-06-30
Duration (months): 58.0
Total project cost (EUR): 5930520.0
EU funding (EUR): 4201501.5
Participants: 10
Project status: CLOSED

Biomass is a valuable, sustainable feedstock for the production of high added value chemicals and materials, and will play an important role in the transition of the European Process Industry to a Sustainable Process Industry. However, for the optimal utilization of these bio-resources the fractionation of the biomass on basis of functionalities is required. The innovative approach of BIO4PRODUCTS is to apply a short thermal treatment at elevated temperature enabling the fractionation of the bio-resource, but keeping the key chemical functionalities in separate, depolymerized fractions. Within the project the process will be demonstrated in a 3 t/d demo-plant. Subsequently, BIO4PRODUCTS will demonstrate the use of the resulting intermediate processing streams for the production of wood preservation products, furanic resins, phenolic resins and roofing material as cost-effective renewable alternatives for fossil resources in the conventional products (30-100% substitution). Each of the steps in the whole chain has at least been proven on bench-scale (TRL5) and should reach TRL 6-7 by execution of this project. The feedstock flexibility will be shown by demonstrating the complete chain for 4 different biomass resources representative for the majority of biomass resources available in Europe. Integral topics covered by the project are the techno-economic and environmental assessments as well as the development of business plans for subsequent commercialization of the individual product lines and the overall value chain. The BIO4PRODUCTS consortium consists of 2 large industries and 4 SME’s and 1 one non-profit organization covering the whole chain from biomass collection, primary and secondary conversion, and final use in end products. Additionally, specific expertise is included on environmental evaluation and the market introduction of sustainable products.

Keywords: bio resources,optimal utilisation,flexible value chain,demonstration,key functionalities,process industry,pyrolysis,lignin,sugars
Research Infrastructures for the control of vector-borne diseases (INFRAVEC2)

Framework: Horizon 2020 — Excellent Science
Programme: Research Infrastructures
Theme: Research infrastructures
Destination: Integrating activities and infrastructures
Action type: Research and Innovation actions
Countries involved: Italy,Germany,Germany,Spain,Italy,Switzerland,Switzerland,Serbia,Greece,France,France,New Caledonia,Czechia,Netherlands,Netherlands,United Kingdom,United Kingdom,United Kingdom,Mali,Burkina Faso,United Kingdom,Senegal
Call: Integrating Activities for Advanced Communities (H2020-INFRAIA-2016-1, 2016)
Start date: 2017-02-01
End date: 2022-06-30
Duration (months): 65.0
Total project cost (EUR): 9998845.25
EU funding (EUR): 9998845.25
Participants: 25
Project status: CLOSED

The overall objective of the Infravec2 project is to integrate key specialized research facilities necessary for European excellence in insect vector biology, to open the infrastructure for European access, and to develop new vector control measures targeting the greatest threats to human health and animal industries. Infravec2 is an Advanced Community, following a four-year Starting Community lifecycle (FP7 Infravec1). Lack of access to key infrastructures limits European vector research and impedes development of vector control measures. Insect vectors transmit parasitic diseases such as malaria and leishmaniasis, and viral infections such as chikungunya, dengue, Zika, Japanese encephalitis and yellow fever. Vector-borne diseases, which have historically been a problem of tropical countries, now represent a threat for temperate regions of the world including much of Europe. The 24 consortium partners, including 4 commercial companies, hold the major European biosecure insectaries for experimental infection and containment of insect vectors under Containment Level 2 and 3 (CL2/CL3) conditions, other key insect vector facilities, and include front-line field sites in Africa, the Pacific, and the Americas. Infravec2 will implement comparable standards across the secure insectary facilities as a world first, improving exploitation of European vector infrastructures for research and public health, and will develop other innovative methodologies and technologies. Networking activities will assure that the project achieves full impact, producing a step change in European vector biology research and the product pipeline, and consolidating European global leadership in insect vectors. The goal of the Infravec2 project is to build a durable European infrastructure to control insect vector-borne disease, including with power to predict and prevent the inevitable next epidemic outbreak in advance.

Keywords: insect vector,mosquitoes,sandflies,tsetse fly,culicoides,aedes,anopheles,culex,arbovirus,malaria,zika,dengue,chikungunya,rift valley fever,west nile virus,leishmania,phlebovirus
DNA repair mechanisms and therapy resistance of BRCA2-deficient cancers (DREMATURE)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Individual Fellowships (IF)-Standard European Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Life Sciences
Countries involved: Switzerland
Call: Individual Fellowships (H2020-MSCA-IF-2016, 2016)
Start date: 2018-01-01
End date: 2019-12-31
Duration (months): 24.0
Total project cost (EUR): 187419.6
EU funding (EUR): 187419.6
Participants: 1
Project status: CLOSED

Despite the existence of various novel anti-cancer treatments, drug resistance remains a major cause of death in patients with disseminated cancer. To increase specificity and efficacy, modern treatment strategies in molecular oncology employ the “synthetic lethality” concept. An example are BRCA1/2-deficient breast and ovarian cancers that lack DNA repair by homologous recombination (HR). Due to this defect, tumor cells rely more on other DNA repair pathways. When such alternative pathways are jammed, e.g. by poly(ADP-ribose) polymerase inhibitors (PARPi), normal cells with intact HR can survive, whereas cancer cells die. However, even with this sophisticated treatment strategy, resistance to PARPi still occurs and greatly reduces patient survival. The mechanisms driving this resistance are still largely unknown. The main goal of this project is to advance the knowledge on therapy resistance by using a genetically engineered mouse model of BRCA2-deficient breast cancer, which closely mimics the human disease. Like in patients, cancer cells in these animals eventually escape from therapy. I will start by synergizing the next generation sequencing analysis of spontaneous resistant mouse tumors with functional genetic screens using the CRISPR/Cas9 technology. This combination has yielded interesting candidate genes whose loss of function may cause resistance. Two promising candidates, MDC1 and Claspin, will be further investigated using innovative and physiologically relevant 3D tumor organoid cultures. Moreover, I will apply my expertise in modern imaging technology to develop novel approaches to visualize DNA repair dynamics in resistant tumors in vitro and in vivo. I am convinced that by understanding basic resistance mechanisms, smart biosensors can be built to image the DNA damage response and eventually improve clinical decision making. I believe this project will have an impact on the design of strategies to overcome therapy escape in human cancer patients.

Keywords: drug resistance,brca2,parp inhibition,dna repair,breast cancer,genetically engineered mouse models,3d cancer organoids
CETOCOEN Excellence (CETOCOEN Excellence)

Framework: Horizon 2020 — Spreading excellence and widening participation
Programme: Widening participation and spreading excellence
Theme: Improved access to Excellence
Action type: Coordination and support actions
Countries involved: Austria,Switzerland,Czechia,United Kingdom
Call: Teaming Phase 1 (H2020-WIDESPREAD-04-2017-TeamingPhase1, 2017)
Start date: 2017-09-01
End date: 2018-08-31
Duration (months): 12.0
Total project cost (EUR): 384867.5
EU funding (EUR): 384867.5
Participants: 5
Project status: CLOSED

The aim of this project is to exploit research capacities built in Central Europe with a support of the European Structural and Investment Funds and develop a cutting-edge research platform capable of addressing major scientific and societal challenges of the contemporary Europe in the area of Environment and Health. It will enhance a scientific value of existing regional population studies and turn them into the accessible source of valuable information by developing sustainable biobanking platform and harmonizing their protocols, questionnaires, and standard operation procedures to allow for their joint assessment and interpretation of results. Existing research programmes will be expanded to address questions related to a wider range of factors (generically called exposome) impacting human health and wellbeing. To identify new biomarkers of exposures, effects, and susceptibility to pathologies, innovative approaches to the assessment of multiple exposures have to be developed including omics technologies, novel methods for integrative analysis, software tools and computational models, chemical sensors and triggers allowing for tracing such processes in biological systems. This innovative research is well aligned with the European and national strategic priorities and documents (including the National Innovation Strategy), and will generate substantial new knowledge needed for prioritisation of future research and policy actions in the area of chemical management as well as practical tools applicable in health protection, prevention, diagnostics, and intervention with the aim of minimizing the burden of disease, improve the health and well-being of citizens and lower health costs.

Keywords: human health,human exposure,exposome,risk assessment,bioinformatics,biomarkers,microfluidics,epidemiology,cohort,vulnerable population,ageing,environmental contamination,trace analysis
Super-resolution genomic mapping for the microbiome (METAMAPPER)

Framework: Horizon 2020 — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Proof of concept grants
Action type: ERC actions
Countries involved: Belgium
Call: ERC-Proof of Concept (ERC-2017-PoC, 2017)
Start date: 2017-12-01
End date: 2019-05-31
Duration (months): 18.0
Total project cost (EUR): 149875.0
EU funding (EUR): 149875.0
Participants: 1
Project status: CLOSED

Animals and bacteria have been working together for about as long as they have co-existed, long before the advent of mankind. The bodies of our ancient ancestors offered protected, nutrient-rich habitats for bacteria. In return, animals could take an evolutionary short-cut to developing new capabilities by ‘borrowing’ bacterial genes. Indeed, when gut bacteria assist with the digestion of e.g. dietary fiber, the resulting metabolites will subsequently exert an influence on an intricate network of host molecular pathways. Gut microbiota, in addition to host genetics, can therefore constitute a major factor in the etiology of complex disorders, ranging from obesity, cardiovascular disease, autoimmune disease (multiple sclerosis, rheumatoid arthrosis), inflammation (inflammatory bowel disease, Crohn’s) to neurological conditions. Although such a key role for the human microbiomes had been postulated for some time, many details on the delicate interplay between flora and host remained unknown, largely because suitable methods for uncovering these host-guest interactions were simply not available. These technological barriers keep the diagnostic and therapeutic potential of the microbiome largely untapped. In this project, we will validate the FLUROCODE genomic mapping technology as an alternative to shotgun sequencing and amplicon based techniques for microbiome studies. This will extend the benefits of genomic mapping techniques to complex sample analysis. Through a head-to-head comparison with the state of the art in metagenomic analysis, the POC data will serve as a key enabler for the transfer of the technology platform into a separate venture, working towards diagnostic applications and developing METAMAPPER based microbiome screening as a routine medical tool. The METAMAPPER microbiome readout technology is be perfectly placed to be part of the evolution of microbiome analysis to clinical application.

Keywords: microbiome,genomic mapping,super resolution fluorescence microscopy
Collaborating for the excellence of public entities for business promotion. An example of policies aimed at the improvement of the competitiveness of the regional enterprises throughout the EFQM (CooExcell2015)

Framework: Horizon 2020 — Industrial Leadership
Programme: Innovation in SMEs
Action type: Coordination and support actions
Countries involved: Spain,Romania,Norway
Call: peer learning of innovation agencies (H2020-INNOSUP-2014-5, 2014)
Start date: 2015-09-01
End date: 2016-04-30
Duration (months): 8.0
Total project cost (EUR): 15000.0
EU funding (EUR): 15000.0
Participants: 3
Project status: CLOSED

The objective consists on using the "EFQM Framework for Innovation Agencies" as a tool for self-assessment by ADER (Spain), with a peer learning approach in which 2 other European Innovation or Economic Agencies participate. The project will end achieving the deliverable 'Recognised for Excellence EFQM assessment' that provides training and learning for all bodies involved in the process. This proposal is in line with the objectives of ADER, in its guidance to incorporate innovation and excellence as elements for improving the competitiveness of companies in La Rioja. ADER is a Spanish public agency aiming to improve the competitiveness of companies in La Rioja by promoting research, innovation and technological development, internationalization and promotion abroad, business excellence and corporate design through different instruments and technical and financial support services for the companies. One of its strategic objectives is to promote the use of the EFQM model by companies in La Rioja through a program developed since 2007 called Business Excellence ADER. The programme aims to encourage companies to advance in the development of its management system, in line with the principles of excellence. The programme helds every year “Rioja Recognition and Awards for Business excellence”. ADER has internalized in its organization the approach to quality and excellence with a clear orientation to the citizen. It has certified the provision of services through a system of Quality Management and Environmental according to the UNE-EN-ISO 9001, UNE ENE ISO 14001, and the Accessibility Certification ICT AENOR according to the UNE 139803. ADER operates by applying the EFQM model, and want to go a step further by contrasting it with other Innovation Agencies, with the aim to: • improve their systems and advance the process of recognition for excellence. • acquire new knowledge to facilitate the the promotion and dissemination of the EFQM model among enterprises.

Keywords: ader promotes the implementation of improved corporate governance through excellence in business in the region of la rioja through a simplified model of excellence
Probing new physics with Coherent Elastic Neutrino-Nucleus Scattering and a tabletop experiment (CENNS)

Framework: Horizon 2020 — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Starting grants
Action type: ERC actions
Panel: Fundamental constituents of matter
Panel description: Particle, nuclear, plasma, atomic, molecular, gas, and optical physics
Countries involved: France
Call: ERC Starting Grant (ERC-2018-STG, 2018)
Start date: 2019-02-01
End date: 2025-01-31
Duration (months): 72.0
Total project cost (EUR): 1495000.0
EU funding (EUR): 1495000.0
Participants: 1
Project status: SIGNED

Ever since the Higgs boson was discovered at the LHC in 2012, we had the confirmation that the Standard Model (SM) of particle physics has to be extended. In parallel, the long lasting Dark Matter (DM) problem, supported by a wealth of evidence ranging from precision cosmology to local astrophysical observations, has been suggesting that new particles should exist. Unfortunately, neither the LHC nor the DM dedicated experiments have significantly detected any exotic signals pointing toward a particular new physics extension of the SM so far. With this proposal, I want to take a new path in the quest of new physics searches by providing the first high-precision measurement of the neutral current Coherent Elastic Neutrino-Nucleus Scattering (CENNS). By focusing on the sub-100 eV CENNS induced nuclear recoils, my goal is to reach unprecedented sensitivities to various exotic physics scenarios with major implications from cosmology to particle physics, beyond the reach of existing particle physics experiments. These include for instance the existence of sterile neutrinos and of new mediators, that could be related to the DM problem, and the possibility of Non Standard Interactions that would have tremendous implications on the global neutrino physics program. To this end, I propose to build a kg-scale cryogenic tabletop neutrino experiment with outstanding sensitivity to low-energy nuclear recoils, called CryoCube, that will be deployed at an optimal nuclear reactor site. The key feature of this proposed detector technology is to combine two target materials: Ge-semiconductor and Zn-superconducting metal. I want to push these two detector techniques beyond the state-of-the-art performance to reach sub-100 eV energy thresholds with unparalleled background rejection capabilities. As my proposed CryoCube detector will reach a 5-sigma level CENNS detection significance in a single day, it will be uniquely positioned to probe new physics extensions beyond the SM.

Keywords: low energy and rare event searches for astroparticle physics
Thermal-aware Resource Management for Modern Computing Platforms in the Next Generation of Aircraft (THERMAC)

Framework: Horizon 2020 — Societal Challenges
Programme: Smart, green and integrated transport
Theme: Public-private partnerships
Destination: Clean Sky 2
Action type: Research and Innovation actions
Partnership: CS2 (Art-187)
Countries involved: Czechia,Portugal
Call: Improved Thermal Properties of Computing Platforms for Next-Generation Avionics [SAT] (H2020-CS2-CFP08-2018-01, 2018)
Start date: 2019-04-01
End date: 2022-01-31
Duration (months): 34.0
Total project cost (EUR): 793375.0
EU funding (EUR): 793375.0
Participants: 2
Project status: CLOSED

The THERMAC project aims to investigate, develop, and validate emerging thermal-aware software-based techniques that will reduce operating temperature of avionic computing platforms in small aircraft transports. The project specifically targets the integration of multicore and GPU-based platforms in avionics from a thermal perspective. The expected impact of the improved thermal performance will improve dependability, computing performance, and will reduce size and weight of electronics due to relaxed dissipation requirements and the higher number of functionalities that can be integrated in the same computing platform.

Keywords: thermal aware resource management,multicore platforms,small aircraft transport